

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class

Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that a poster, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.

Title: “Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy”

Session Category: Trials in Progress (TIP); Poster Session - Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract Number: TPS4185

Date and Time: Monday, June 5, 2023, 8:00 AM-11:00 AM

About NMS-153

NMS-153 is a potent and highly selective small molecule inhibitor of Monopolar Spindle 1 (MPS1, also known as TTK kinase) with differentiated mechanism of action. MPS1 kinase is highly expressed in proliferating cells, including cancer cells and plays a critical role in the control of mitosis and ensuring faithful chromosome segregation. Inhibiting MPS1 results in high level of genomic instability and poly/aneuploidy causing senescence and apoptosis. Currently, NMS-153 is in early clinical development phase in adult patients with unresectable hepatocellular carcinoma (HCC).

About Nerviano Medical Sciences

[Nerviano Medical Sciences](https://www.nervianoms.com) S.r.l. (NMS) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which originate from our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies. Our kinase platform has enabled us to out-license IP rights on approved innovative medicines such as encorafenib and entrectinib and currently includes preclinical to clinical stage products, which are being developed both in house and with partners, including four proprietary clinical assets in Phase I/II studies. Moreover, the development of our payload linker platform allows an extension of our pipeline with innovative payload linkers for next generation ADC production.

NMS combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with a global vision and a broad range of expertise in drug discovery and development. We collaborate with academia and clinical investigators as well as industrial partners worldwide to advance our programs from early

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

discovery to clinical development of new drugs. The recently signed collaboration agreement with licensing option with Merck Healthcare KGaA for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.

We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising pre-clinical assets.

About NMS Group

[NMS Group](#) S.p.A. (NMS Group) is the largest R&D company in Italy committed to the discovery and development of novel oncological therapies and through its three subsidiaries is the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product with more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing.

NMS Group's three subsidiaries are: NMS S.r.l., focused on discovery and clinical development of new drugs for oncology at Nerviano (Italy) and Boston (US) sites, Accelera S.r.l., one of the few Italian CROs capable of providing support through all phases of drug research and development, and NerPharMa S.r.l., a CDMO owing a wide and cutting edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it